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Severe acute respiratory syndrome coronavirus 2 
(SARS- CoV-2) is an RNA virus first reported in humans 
in Wuhan, China, in December 2019. The virus has since 
spread rapidly worldwide causing coronavirus disease 
2019 (COVID-19), which continues to have a devas-
tating effect on global health1. The majority of patients 
with SARS- CoV-2 infection remain asymptomatic or 
have mild symptoms, including fever, cough, anosmia 
and headache. However, around 15% develop severe pul-
monary disease typically over 10 days, leading to respira-
tory compromise, which might progress to multi- organ 
failure, coagulopathy and death2–4. Oxygen supplementa-
tion, invasive ventilation and other supportive measures 
now form part of the standard- of- care in hospitalized 
patients; however, mortality remains high among those 
with critical disease. Common risk factors consistently 
associated with severe COVID-19 are now well estab-
lished and include advancing age, male sex and a burden 
of comorbidity, including hypertension, heart disease, 
diabetes and malignancy5,6.
As the pandemic has evolved, most policy- makers, 
supported by a growing body of scientific evidence, have 
sought to protect their populations from infection. Those 
most at risk of severe COVID-19 have been advised to 
‘shield’, effectively avoiding all social contact with others. 
A detailed understanding of the contribution of specific 
disease phenotypes to COVID-19 susceptibility and clin-
ical outcomes has been crucial to enable the tailoring of 
public health advice to specific patient subpopulations.
In parallel, randomized clinical trials continue to eval-
uate therapeutic strategies against SARS- CoV-2, includ-
ing direct antiviral and immune- modifying agents7,8. 
Understanding which patient groups require early or 
novel therapeutic interventions is a high clinical prior-
ity. In addition, SARS- CoV-2 vaccine development has 
progressed at an unprecedented rate, with the leading 
candidates all publishing extremely promising safety and 
efficacy data from phase III trials. There will now be an 
unprecedented global demand for vaccine deployment 
and, therefore, establishing which patients are most 
vulnerable to adverse COVID-19 outcomes is neces-
sary to help inform who is prioritized in immunization 
programmes.
Since the onset of the pandemic there has been con-
cern that pre- existing chronic liver disease (CLD) might 
predispose to poor outcomes following SARS- CoV-2 
infection, particularly due to the overlapping risk factors 
for severe COVID-19 and CLD, for example, advancing 
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age, obesity and diabetes. In addition, advanced liver 
disease is associated with immune dysregulation and 
coagulopathy, which could contribute to a more severe 
COVID-19 course9,10. The global burden of CLD is vast, 
with cirrhosis affecting more than 122 million peo-
ple worldwide, of whom 10 million have decompen-
sated disease11. Understanding the natural history of 
COVID-19 in patients with CLD, across different aetio-
logies and across the spectrum of liver disease severity, 
is therefore paramount.
This Review focuses on the pathogenesis and con-
sequences of SARS- CoV-2 infection in patients with 
CLD based on evidence rapidly acquired through large 
international cohorts throughout 2020. We also explore 
the utility of liver biochemistry as a prognostic tool dur-
ing COVID-19, summarize the evidence for direct viral 
infection of liver cells and explore the likely mechanisms 
underlying SARS- CoV-2- related liver injury. Finally, we 
discuss the profound effect of the pandemic on hepatol-
ogy services and patient behaviours, which could lead to 
an increase in future liver disease incidence and severity.
Hepatotropism of SARS- CoV-2
The tissue reservoirs for SARS- CoV-2 replication 
remain to be fully elucidated, partly due to difficulties 
in accessing biopsy samples from actively infected indi-
viduals and the requirement for high level laboratory 
containment facilities. The virus spike protein binds 
ACE2 to gain cell entry and transmembrane serine pro-
tease 2 (TMPRSS2) and paired basic amino acid cleav-
ing enzyme (FURIN) are also important for infection; 
therefore, the expression of these receptors provided 
early clues for putative hepatic permissive cells.
Single- cell RNA sequencing analyses in healthy liv-
ers have shown gene expression levels for ACE2 to be 
highest in cholangiocytes (comparable to alveolar type 2 
cells), followed in turn by sinusoidal endothelial cells 
and hepatocytes12,13. TMPRSS2 and FURIN showed 
a broad gene expression profile across many liver 
cell types12. However, in a combined analysis of three 
single- cell RNA sequencing datasets from liver tis-
sue from healthy individuals, very few hepatocytes 
co- expressed ACE2 and TMPRSS2 (ref.14). Experimental 
cellular and organoid models have therefore been 
important in trying to decipher the permissibility of 
liver cell types to SARS- CoV-2 infection. Hepatocellular 
carcinoma- derived cell lines Huh-7 and HepG2 are able 
to support the complete viral life cycle15; however, rep-
lication in primary hepatocytes has not yet been con-
firmed. This discrepancy between cellular models could 
be related to the presence of cancer- associated mutations 
in hepatoma cell lines, such as the tumour suppressor 
p53, which, under normal conditions, serves to downreg-
ulate intracellular SARS- CoV-2 replication16. Zhao et al. 
generated ACE2- expressing and TMPRSS2- expressing 
human liver ductal organoids that were able to recapit-
ulate SARS- CoV-2 infection17, suggesting that the bile 
duct epithelium could support pseudoparticle entry. It is 
worth noting that the seemingly high SARS- CoV-2 entry 
receptor expression and viral permissibility of cholan-
giocytes is at odds with the non- cholestatic pattern of 
liver biochemistry typically found in COVID-19; the 
precise reasons for this aspect are currently unknown. 
However, it is possible that SARS- CoV-2 can undergo 
low level replication in cholangiocytes in vivo without 
triggering cell death. This process would be consistent 
with other reservoirs of long- term viral replication, such 
as in the small intestine, which can help shape memory 
B cell responses to the virus over time18. Human pluri-
potent stem cell- derived liver organoids comprising 
mostly albumin- expressing hepatocytes have also been 
shown to express ACE2 and permitted SARS- CoV-2 
pseudoparticle entry19.
The influence of liver injury and underlying liver 
disease on the hepatotropism of SARS- CoV-2 remains 
unclear and no studies have yet specifically explored the 
histological changes found in patients with COVID-19 
and pre- existing CLD. However, early studies in the 
era preceding COVID-19 found a greater than 30- fold 
increase in ACE2 expression in the liver of patients 
with hepatitis C virus- related cirrhosis compared with 
healthy individuals20. In addition, liver mRNA expres-
sion of ACE2 and TMPRSS2 was upregulated in 
non- infected patients with obesity and nonalcoholic 
steatohepatitis but not with steatosis alone21. Similarly, 
rodent models of liver injury via bile duct ligation have 
been associated with increased hepatic ACE2 expression 
and activity in parallel with markers of hypoxia20,22. Liver 
injury and inflammation could potentiate SARS- CoV-2 
hepatotropism by modulating viral receptor expression, 
with ACE2 being identified as an interferon- inducible 
gene in human respiratory epithelia23,24. However, this 
finding must be interpreted with caution, as it might 
be the truncated isoform of ACE2, termed deltaACE2, 
rather than the viral receptor molecule itself that is 
being upregulated25. Whilst the tissue- specific factors 
controlling SARS- CoV-2 infection are poorly under-
stood, there is an increasing recognition of the role of 
additional accessory receptors in viral entry. It has been 
shown that the high- density lipoprotein scavenger recep-
tor B type 1 (SR- B1) helps facilitate ACE2- dependent 
coronavirus attachment in vitro26, reminiscent of hepati-
tis C virus infection27. Furthermore, treatments targeting 
SR- B1 reduced the lipoprotein- mediated enhancement 
Key points
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following SaRS- Cov-2 infection compared with the matched general population.
•	The pandemic has been associated with increased alcohol consumption, unhealthy
eating habits, and interruptions to hepatology services, which might lead to an 
upward trend in liver disease incidence and severity.
of SARS- CoV-2 infection26. However, the histological 
assessment of liver tissue in this study confirmed only 
sparse hepatic ACE2 expression.
To obtain liver tissue and detect viral infection 
during the short window of active respiratory illness 
is technically and clinically challenging. However, 
extrapulmonary infection is recognized, particularly 
in the gastrointestinal tract, with stool SARS- CoV PCR 
remaining positive for up to a week after viral clearance 
from the lungs28. Furthermore, pervasive infection of 
enterocytes has been well documented29,30, with viral 
protein and RNA found to persist in intestinal biopsies 
for many months after clinical infection has resolved18. 
In post- mortem wedge liver biopsy samples from 
48 patients dying from severe COVID‐19 lung disease, 
SARS- CoV-2 was detected via in situ hybridization in 
68% of samples31. Histological assessment also revealed 
vascular abnormalities characterized by portal venous 
and sinusoidal microthromboses (100%), microvesic-
ular and macrovesicular steatosis (50%), mild portal 
inflammation (66%), and portal fibrosis (60%). The 
latter finding could suggest a degree of underlying liver 
disease, most likely secondary to nonalcoholic fatty 
liver disease (NAFLD) given that metabolic risk factors, 
including hypertension and cardiovascular disease, were 
enriched in this cohort. Again, the absence of histolog-
ical evidence of biliary injury is conspicuous given the 
degree of cholangiocyte viral entry receptor expression. 
Post- mortem electron microscopy of liver tissue in a case 
of fatal respiratory COVID-19 has also directly visualized 
possible coronavirus- like particles in hepatocyte cyto-
plasm in association with mitochondrial swelling and 
apoptosis32. This finding would be consistent with large 
protein interaction maps that have identified connec-
tivity between NSP5, the main protein of SARS- CoV-2, 
and mitochondrial components33. Conversely, in- depth 
proteomic assessment of autopsy tissue from 19 patients 
with COVID-19 revealed little evidence of active viral 
replication in the liver34. However, hepatic protein sig-
natures did indicate upregulated profibrotic pathways, 
dysregulated fatty acid oxidation and oxidative phos-
phorylation, and markers of immune activation. This 
shifting proteomic landscape was found to be associated 
with the presence of multi- organ dysfunction, hepatic 
steatosis and coagulative hepatocyte necrosis34.
Whilst there is variation in viral entry receptor 
expression profiles across the different in vitro and 
in vivo liver models (fig. 1), direct evidence of specific 
SARS- CoV-2 hepatotropism is lacking. Given the poor 
outcomes and high rates of hepatic decompensation 
in patients with cirrhosis and COVID-19, more work 
is needed to determine the pathogenic role of direct 
hepatic viral infection and the mechanisms leading 
to hepatic decompensation in patients with underlying 
liver disease.
Liver biochemistry in COVID-19
Patterns and frequency of liver biochemistry abnor-
malities in COVID-19. Although the precise influence 
of COVID-19 on the liver remains unclear, abnormal-
ities in liver biochemistries are common in patients 
with COVID-19, occurring in approximately 15–65% 
of SARS- CoV-2- infected individuals35–42. The wide 
range in these reported frequencies could be attribut-
able to different definitions of upper limit of normal, 
varying laboratory values considered as liver enzymes, 
and geographical variability in the prevalence and type 
of underlying CLD43. Liver biochemistry abnormali-
ties in COVID-19 are generally characterized by mild 
(1–2 times the upper limit of normal) elevations of 
serum alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels, reported in an estimated 
29–39% and 38–63% of patients, respectively36–38,44. 
Hypoalbuminaemia, a non- specific marker of illness 
severity, has been reported to be associated with worse 
COVID-19 outcomes45, but severe liver injury, elevation 
in serum bilirubin level and liver synthetic dysfunc-
tion are all rare in patients infected with SARS- CoV-2 
(refs41,42,44). Abnormalities in liver biochemistries are 
reported in similar frequencies regardless of the presence 
of pre- existing liver disease46.
Underlying causes of elevated liver enzymes in COVID-19. 
There are a number of potential contributors to ele-
vated liver enzyme levels in COVID-19. Liver biopsy 
results in patients with SARS- CoV-2 have been charac-
terized by non- specific findings, including steatosis, 
mild lobular and/or portal inflammation, and vascular 
pathology31,47,48. In most cases, abnormal biochemistries 
are likely multifactorial with potential contrib utions 
from immune- mediated inflammatory response, drug- 
induced liver injury, hepatic congestion and extra-
hepatic release of transaminases49 as well as possible 
direct infection of hepatocytes.
Among hospitalized patients with COVID-19, eleva-
tions of serum AST levels positively correlate with lev-
els of ALT but not with markers of muscle breakdown 
(such as creatinine kinase) or systemic inflammation 
(such as C- reactive protein (CRP) and ferritin)50. These 
findings imply that elevated liver enzymes in COVID-19 
result from direct hepatic injury, although COVID-19- 
 associated rhabdomyolysis is rarely reported51. Lastly, 
AST is often found to exceed ALT during the course 
of COVID-19, which would be atypical for a classic 
hepatocellular pattern of liver injury outside of specific 
contexts such as alcohol- related liver disease, certain 
drug- induced liver injuries (for example, lamotrigine), 
ischaemic hepatitis and cirrhosis50. The mechanisms 
responsible for an AST- predominant aminotrans-
ferase elevation remain incompletely defined but could 
include COVID-19- related mitochondrial dysfunction33, 
SARS- CoV-2- induced hepatic steatosis31 and altered 
hepatic perfusion secondary to microthrombotic 
disease31,52. A systemic review and meta- analysis of 
biopsy and autopsy studies reported the prevalence 
of hepatic vascular thrombosis in COVID-19 to be 
29%53. Systemic hypoxia in COVID-19 might also have 
a contributory role and, interestingly, AST elevations 
have previously been reported with other viral pneu-
monias, including influenza A H1N1 infection, where 
levels increased in parallel with diminishing peripheral 
oxygen saturations54.
As with many other infections, SARS- CoV-2 is asso-
ciated with systemic inflammation that could contribute 
to elevations in liver biochemistries via cytokine release55. 
Patients with substantial elevations in serum ALT lev-
els often have high levels of CRP (which is synthesized 
by the liver), D- dimer, ferritin and IL-6 (refs44,45,56,57). 
IL-6, which is produced by monocytes, macrophages 
and T cells in response to activation of the innate and 
adaptive immune system, is the key driver of CRP pro-
duction and high IL-6 levels are associated with liver 
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Fig. 1 | Hepatotropism of SARS-CoV-2. Understanding the hepatotropic effects of severe acute respiratory syndrome 
coronavirus 2 (SARS- CoV-2) has required a combination of experimental and clinical models. Hepatoma cell lines in vitro 
have been shown to support the entire life cycle of SARS- CoV-2 (part a, which shows a Huh-7 cell with widespread 
intracellular spike protein staining magenta). In vitro cell models have also demonstrated the role of accessory receptors 
such as high- density lipoprotein receptor scavenger receptor B type 1 (SR- B1) alongside ACE2 for cell entry. In addition, 
both biliary and hepatocyte organoid models have been shown to express necessary viral entry receptors and recapitulate 
SARS- CoV-2 infection (part b). Although there is some variability between gene expression studies regarding the 
distribution of ACE2 on liver cell types, cholangiocytes seem to have the greatest receptor concentration followed by 
hepatocytes (part c); there is also ACE2 upregulation in the parenchyma of cirrhotic livers. Lastly, histological examination 
of livers from patients with fatal respiratory coronavirus disease 2019 (COVID-19) have shown a range of microscopic 
changes such as widespread vascular abnormalities, steatosis and mitochondrial abnormalities (part d). The evidence for 
direct hepatocyte infection remains inconclusive. TMPRSS2, transmembrane serine protease 2. Part a microscopy image 
courtesy of S. Davies, University of Birmingham. Part c adapted with permission from ref.12, Wiley.
injury in COVID-19 (refs44,56). Notably, IL-6 increases 
during COVID-19 illness, declines as patients recover 
and correlates with severity of the disease course58.
There are several other potential contributors to 
abnormal liver biochemistries in COVID-19, includ-
ing ischaemic hepatitis, hepatic congestion related to 
cardiomyopathy, and transaminase release due to the 
breakdown of skeletal and cardiac muscle49. Venous 
and arterial thromboses are now a well- recognized fea-
ture of COVID-19 (refs59–62), including in the liver31,48, 
which could contribute to elevations in liver biochem-
istries. Lastly, drug- induced liver injury is likely to 
contribute to elevated liver enzymes and might have 
been more common early in the pandemic due to the 
use of experimental therapies63. However, no study has 
yet comprehensively mapped the pattern of liver func-
tion tests found within studies over the course of the 
pandemic. Specific COVID-19 treatments implicated 
in cases of drug- induced liver injury include lopinavir– 
ritonavir64,65, tocilizumab66,67 and remdesivir. The hepa-
totoxicity of remdesivir has been subject to debate. 
Although randomized trials in COVID-19 demonstrate 
equivalent liver enzyme elevations between treatment 
and control groups68, screening of the WHO safety 
reports database still reveals a statistically significant 
odds ratio for liver injury with the use of remdisivir69. 
Fortunately, these considerations are likely to become 
less clinically relevant in light of the SOLIDARITY trial 
showing no benefit of remdesivir in hospitalized patients 
with COVID-19 (ref.70).
Prognostic significance of elevated liver enzymes in 
COVID-19. The prognostic significance of elevated 
liver enzymes in patients infected with SARS- CoV-2 is 
currently debated. Some reports have demonstrated that 
elevations of serum liver enzyme levels are associated 
with adverse outcomes, including shock, intensive care 
unit (ICU) admission and mechanical ventilation43,65,71–74. 
However, these studies could be prone to bias if patients 
with severe disease received more intensive laboratory 
monitoring, increasing the likelihood of detecting liver 
injury. Some have reported that there is no apparent 
association between liver enzyme level elevations and 
mortality71,75, whereas others have found that elevated 
liver enzyme levels, and particularly AST and ALT level 
elevations greater than five times the upper limit of nor-
mal, are associated with an increased risk of death42,44,76,77. 
It has been proposed that the prognostic significance 
of elevated liver enzyme levels could be due to a more 
robust host response and aggressive therapies in those 
with severe illness78.
SARS- CoV-2 infection and liver disease
Clinical course and outcomes following SARS- CoV-2 
infection in pre- existing CLD. Patients with CLD and 
especially cirrhosis have multiple mechanisms of 
immune dysfunction that can lead to increased sus-
ceptibility to infection and an aberrant inflammatory 
response during infection — collectively known as 
cirrhosis- associated immune dysfunction (CAID). This 
immune dysfunction includes reduced components 
of the complement system, macrophage activation, 
impaired lymphocyte and neutrophil function, Toll- 
like receptor upregulation, and intestinal dysbiosis9,79. 
Although research attention has mostly focused on 
mechanisms leading to severe bacterial infection80, 
CAID has also been shown to predispose to a variety of 
viral or fungal- related disease81. Whether patients with 
CLD and cirrhosis are more susceptible to SARS- CoV-2 
infection has been the focus of much attention through-
out 2020. Data from both large case series of thousands 
of consecutive patients with COVID-19 and population 
studies using health records do not suggest that patients 
with chronic liver disease are over- represented5,37. In fact, 
electronic health record data from the USA has demon-
strated that patients with cirrhosis are actually at lower 
risk of testing positive for SARS- CoV-2 infection82,83. It 
remains improbable that cirrhosis is protective against 
SARS- CoV-2 acquisition and, therefore, this lower 
rate of positive testing is likely due to a combination of 
increased patient compliance with preventative meas-
ures (for example, social distancing, handwashing) and 
more frequent routine testing. Patients with cirrhosis 
who do acquire infections of all types have been shown 
to have worse clinical outcomes than patients without 
underlying liver disease84,85 and SARS- CoV-2 infection 
seems to follow a similar pattern.
The aetiology of liver disease could influence clini-
cal outcome in COVID-19. In the general population, 
advancing age, obesity and diabetes are risk factors 
for COVID-19 morbidity and mortality5; however, in 
these series, such patients were not explicitly diagnosed 
with NAFLD, in part because hepatic steatosis was 
not recorded or because alcohol use was not assessed. 
Indeed, there are wide inconsistencies throughout 
the literature regarding the influence of NAFLD on the 
COVID-19 course. This inconsistency could be related 
to difficulties in separating the effect of NAFLD from 
other metabolic comorbidities, due to the confounding 
effect of viral- induced steatosis or because of varying 
diagnostic criteria. The latter is of particular impor-
tance currently as the global hepatology community 
grapples with the proposed classification changes from 
NAFLD to metabolic dysfunction- associated liver 
disease86. One retrospective series of 202 consecutive 
patients with SARS- CoV-2 infection identified NAFLD 
as a risk factor for progressive COVID-19, abnormal 
liver enzyme levels and longer viral shedding time87. 
Another study in 327 patients showed an intersection 
between NAFLD and the risk of severe COVID-19 in 
patients under 60 years of age88. Similarly, MRI data 
from 287 patients tested for SARS- CoV-2 (79 posi-
tive, 208 negative) demonstrated that individuals with 
obesity and a concomitant liver fat fraction of ≥10% 
were at threefold increased risk of developing sympto-
matic laboratory- confirmed COVID-19 (available as a 
non- peer- reviewed Preprint only)89. However, in a series 
of 155 consecutive inpatients with COVID-19, the pres-
ence of steatosis (in 43%) was not independently asso-
ciated with mortality90. These findings were confirmed 
in a larger international cohort of 745 patients with 
CLD and cirrhosis from 29 countries collected using 
the SECURE- Cirrhosis and COVID- Hep registries in 
which the odds ratio for death for patients with NAFLD 
was 1.01 (95% CI 0.57–1.79)91. In this same study, 
alcohol- related liver disease was the only liver disease 
aetiology with a significant odds ratio for death (1.79, 95% 
CI 1.03–3.13)91. Registry data for 70 patients with auto-
immune hepatitis and SARS- CoV-2 infection has also 
shown equivalent outcomes to patients with CLD of 
other aetiology and to propensity score- matched con-
trols despite the use of baseline immunosuppression in 
86% of cases92. In multiple series, the main cause of death 
in CLD patients was COVID-19- induced pulmonary 
disease followed by liver- related mortality91,93.
Among patients with prevalent liver disease, once 
infected with SARS- CoV-2, there is a stepwise increase 
in morbidity and mortality with increasing severity 
of cirrhosis as measured by Child–Pugh (CP) class. 
Although the proportion of patients hospitalized in the 
SECURE- Cirrhosis and COVID- Hep registries was no 
different among patients with CLD and CP classes A, 
B and C, there was a stepwise increase in frequency of 
ICU admission, renal replacement therapy, invasive 
ventilation and death. There was also an increase in 
mortality for all patients as they required more intense 
medical support, with patients classed as CP- C hav-
ing only a 10% survival once undergoing mechanical 
ventilation (fig. 2). After adjusting for baseline charac-
teristics, COVID-19- related mortality was signifi-
cantly associated with the severity of pre- existing liver 
cirrhosis and the odds ratio for death increased across 
the stages of cirrhosis: CP- A 1.90 (95% CI 1.03–3.52), 
CP- B 4.14 (95% CI 2.24–7.65) and CP- C 9.32 (95% 
CI 4.8–18.08)91. Notably, registry data are vulnerable 
to reporting bias of more severe cases, which likely 
accounts for the inclusion of predominantly hospital-
ized patients in these studies. However, it is reassuring 
that the SECURE- Cirrhosis and COVID- Hep registries 
included a large proportion of patients without cirrhosis 
and with non- severe COVID-19 and that mortality was 
consistent with a range of other smaller cohorts (Table 1). 
A summary of studies reporting outcomes in patients 
with SARS- CoV-2 and pre- existing liver disease is pre-
sented in Table 1. Although the acute mortality associ-
ated with COVID-19 in patients with cirrhosis is high, in 
those who survive the initial insult, the rates of death and 
re- admission at 90- days are comparable to those with 
cirrhosis alone94. Therefore, beyond the acute infective 
period, SARS- CoV-2 infection does not seem to precip-
itate liver disease progression over and above the natural 
history of cirrhosis.
COVID-19 can cause acute- on- chronic liver failure 
(ACLF). Although traditionally associated with bacte-
rial infections, viral illness can also precipitate ACLF85,95, 
which is marked by both liver- specific decompensation 
and increasing severity and frequency of extrahepatic 
organ system failure96. In the SECURE- Cirrhosis and 
COVID- Hep registries, hepatic decompensation events 
were more frequent with increasing severity of liver 
disease and mortality increased with worsening ACLF 
as measured by the CLIF- C score91,93,97. CAID likely 
underlies the intersection between severe COVID-19 
pulmonary disease and ACLF. Cirrhosis is known to 
be associated with an increase in baseline endotoxemia 
and cytokine production that can lead to an exaggerated 
inflammatory response in the setting of infection (fig. 3). 
This aspect might be particularly severe in patients with 
alcohol- induced liver disease98, potentially explain-
ing the increased mortality in this group91. It has also 
been shown that gut microbiota composition plays a 
role in regulating the magnitude of COVID-19 sever-
ity, possibly via modulating host immune responses99. 
Given that cirrhosis is characterized by changes to gut 
microbiota composition and function alongside intesti-
nal permeability100, it is possible that alterations in the 
gut–liver axis might contribute to the severe COVID-19 
course observed in this patient group. However, further 
research into the mechanisms underlying CAID, ACLF 
and COVID-19 are required.
Lastly, the COVID-19 pandemic has unmasked the 
long- entrenched associations between race, socioeco-
nomic status and adverse health outcomes. This issue 
includes patients with CLD for which socioeconomic dis-
parities in American non- Hispanic Black and Hispanic 
communities have been associated with an increased 
risk of SARS- CoV-2 infection101. In addition, racial and 
socioeconomic disparities in internet access have been 
shown to translate into barriers for the use of telehealth, 
particularly video technology, in patients with CLD102.
Specific management of patients with COVID-19 and 
underlying liver disease. The optimal approach to the 
management of patients with underlying liver disease 
who acquire SARS- CoV-2 infection is still evolving. 
However, the characterization of the COVID-19 course 
through multicentre and international cohorts has helped 
optimize the treatment strategies for this patient group, 
as summarized in various consensus guidelines103–105.
Firstly, the recognition that patients with cirrhosis 
are particularly vulnerable to the severe complications 
of COVID-19 is paramount. This recognition should 
encourage a low threshold for SARS- CoV-2 testing 
and consideration of early admission for those with a 
























Fig. 2 | Mortality following SARS-CoV-2 infection according to baseline liver disease 
stage and level of medical support. Rates of mortality in patients with chronic liver 
disease (CLD) and severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) 
infection following hospitalization, admission to intensive care unit (ICU) and invasive 
ventilation separated by liver disease stage. CP, Child–Pugh. Adapted from ref.91,  
CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).
 
Table 1 | Summary of COVID-19 outcome studies in patients with CLD and post- liver transplantation






29 countries; SARS- CoV-2 infection plus 
cirrhosis (n = 386); SARS- CoV-2 plus CLD 
without cirrhosis (n = 359); SARS- CoV-2 plus 
non- CLD (n = 620)
Overall mortality: CP- A (19%), CP- B (35%), CP- C (51%), 
CLD without cirrhosis (8%); increased risk of death 
cirrhosis vs CLD without cirrhosis: CP- A (OR 1.9, 95%  
CI 1.03–3.5), CP- B (OR 4.1, 95% CI 2.4–7.77), CP- C (OR 
9.32, 95% CI 4.80–18); increased risk of death compared 
with propensity score- matched patients without CLD: 






Italy; SARS- CoV-2 plus cirrhosis (n = 50); 
SARS- CoV-2 plus no cirrhosis (n = 399); 
cirrhosis plus bacterial infection (n = 47)
30- day mortality: SARS- CoV-2 plus cirrhosis vs 
SARS- CoV-2 plus no cirrhosis (34% vs 18%; P = 0.030); 
SARS- CoV-2 plus cirrhosis vs cirrhosis plus bacterial 






North America and Canada; SARS- CoV-2 
plus no cirrhosis (n = 108); SARS- CoV-2 plus 
cirrhosis (n = 37); cirrhosis alone (n = 127)
Overall mortality: cirrhosis plus SARS- CoV-2 higher 
mortality compared with patients with SARS- CoV-2 
alone (30% vs 13%; P = 0.03) but not between patients 
with cirrhosis plus SARS- CoV-2 and patients with 






North America; SARS- CoV-2 plus CLD without 
cirrhosis (n = 620); SARS- CoV-2 plus cirrhosis 
(n = 227)
Increased risk of death with decompensated cirrhosis  
(OR 2.91, 95% CI 1.70–5.00); no increased risk with 





13 countries in Asia; SARS- CoV-2 plus CLD 
without cirrhosis (n = 185); SARS- CoV-2 plus 
cirrhosis (n = 43)
Overall mortality: SARS- CoV-2 plus CLD without 





cohort study using 
electronic health 
record data
United Kingdom; 6 million adults: 11,865 with 
cirrhosis, 37 deaths from COVID-19 in patients 
with cirrhosis and 106 hospitalizations with 
COVID-19 in patients with cirrhosis
Hazard ratio for COVID-19- related mortality in patients 
with cirrhosis: women in derivation cohort, 1.8 (95% 





study using electronic 
health record data
North America; SARS- CoV-2 plus cirrhosis 
(n = 305); SARS- CoV-2 plus no cirrhosis 
(n = 9,826); cirrhosis alone (n = 3,301)
Patients with SARS- CoV-2 plus cirrhosis 3.5 times 







18 countries; SARS- CoV-2 plus LT recipient 
(n = 151); SARS- CoV-2 plus non- LT recipients 
from Oxford University Hospitals (n = 627)
Overall mortality (19%); LT did not significantly increase 
the risk of death (absolute risk difference 1.4%, 95% 
CI –7.7 to 10.4); risk factors for mortality within LT 







Spain; SARS- CoV-2 plus LT recipient (n = 111); 
SARS- CoV-2 plus general population during 
study period (n = 150,000); LT recipients 
without SARS- CoV-2 (n = 13,000)
Mortality in LT recipients (18%) lower than the matched 
general population; SMR 95.5 (95% CI 94.2–96.8);  
SIR 191.2 (95% CI 190.3–192.2)
Baseline mycophenolate independent risk factor for 
severe COVID-19 (ICU, IPPV or death) (RR 3.94, 95%  
CI 1.59–9.74; P = 0.003).
Webb et al.129  
(Feb 2021)
Combined analysis 
of Webb et al117 and 
Colmenero et al.115
18 countries including 108 cases from Spain; 
SARS-CoV-2 plus LT recipient (n = 258)
Age and Charlson Comorbidity Index independently 













Health Service Blood 
and Transplant 
registry data
England; SARS- CoV-2 plus LT recipient (n = 64); 
rates of infection and mortality compared 
with all SARS- CoV-2- positive general English 
population
Overall mortality (23%); reduced risk of SARS- CoV-2 






USA; SARS- CoV-2 plus LT recipients (n = 73) 28- day mortality (21%); within whole solid organ 






9 European countries; SARS-CoV-2 plus  
LT recipient (n = 243)
Overall mortality (20%); risk factors for mortality: age, 
diabetes, chronic kidney disease; Tacrolimus had positive 
independent effect of survival (0.55; 95% CI 0.31–0.99)





29 countries; SARS- CoV-2 plus CLD (n = 745); 
SARS = CoV-2 plus ALD (n = 179)







North America; SARS- CoV-2 plus CLD (n = 867); 
SARS- CoV-2 plus ALD (n = 94)
ALD independent risk factor for death (HR 2.42,  
95% CI 1.29–4.55)
common, occurring in 47% of patients with cirrhosis 
and COVID-19, and typically manifests as worsening 
ascites and encephalopathy91, which should be identified 
and managed along traditional lines106. Indeed, hepatic 
decompensation could be the first and only indication 
of SARS- CoV-2 infection in patients with cirrhosis, 
with 24% having no concurrent pulmonary symptoms91. 
Importantly, data have shown that patients with autoim-
mune hepatitis have similar rates of COVID-19- related 
mortality to the matched general population92 and that 
the use of immunosuppression is not an independent 
risk factor for death. This finding should reassure cli-
nicians and provides a clear rationale not to routinely 
reduce immunosuppression in these patients during the 
COVID-19 course.
The trajectory of patients with COVID-19 and 
decompensated cirrhosis at baseline is bleak, with up 
to 80% mortality in those requiring ICU support91, 
although this number might decrease with time as the 
care of patients with COVID-19 continues to improve. 
Notably, the majority of deaths in patients with cirrhosis 
and COVID-19 are from respiratory failure, although 
the precise mechanisms underpinning this observation 
remain unclear. However, it is plausible that pulmonary 
venothromboembolic disease, a hallmark of critical 
COVID-19, has a contributory role given the additional 
hypercoagulable state associated with cirrhosis. Whilst 
routine thromboprophylaxis is universally recommended 
in hospitalized patients with COVID-19, unified risk 
stratification models and treatment algorithms have yet 
to emerge, with wide variation in clinical practice and 
between international guidelines107,108. However, given 
the coagulopathy associated with both cirrhosis and 
COVID-19, the coexistence of these conditions might 
yield a cumulative risk of thrombotic complications103. 
Although it remains to be determined whether enhanced 
venothromboembolic prophylaxis will be of benefit in 
this patient group, studies prior to the COVID-19 pan-
demic showed a benefit of anticoagulation in reducing 
portal pressures109 without an excess bleeding risk110. In 
addition, a multicentre study in northern Italy reassur-
ingly reported no major haemorrhagic complications 
with the use of thromboprophylaxis in 40 patients with 
cirrhosis admitted with COVID-19. Unfortunately, 
patients with advanced cirrhosis are excluded in many 
(but not all) published and active trials investigating 
optimal thromboprophylaxis following admission with 
SARS- CoV-2 infection111,112.
The race to develop specific therapies for COVID-19 
continues at pace. However, an international registry 
study involving 29 countries and 130 different institu-
tions found that patients with cirrhosis were significantly 
Study Design Country/region and number included Major findings





29 countries; SARS- CoV-2 plus CLD (n = 745); 
SARS- CoV-2 plus NAFLD (n = 322)
No independent association with death controlling for 
age, sex, ethnicity, liver disease stage, BMI, CVD, T2DM, 






North America; SARS- CoV-2 plus CLD (n = 867); 
SARS- CoV-2 plus NAFLD (n = 465)
No independent association with death controlling for 







29 countries; SARS- CoV-2 plus CLD (n = 745); 
SARS- CoV-2 plus HBV (n = 96); SARS- CoV-2 
plus HCV (n = 92)






North America; SARS- CoV-2 plus CLD (n = 867); 
SARS- CoV-2 plus HBV (n = 62); SARS- CoV-2 
plus HCV (n = 190)




study using electronic 
health record data
USA; SARS-CoV-2 plus HCV (n = 975), 
SARS-CoV-2 no HCV (n = 975)
SARS-CoV-2 plus HCV more likely to be hospitalised  






29 countries; SARS- CoV-2 plus CLD (n = 745); 
SARS- CoV-2 plus HCC (n = 48)






North America;SARS- CoV-2 plus CLD (n = 867); 
SARS- CoV-2 plus HCC (n = 22); locoregional 
therapy (n = 8), immunotherapy (n = 2)







35 countries; SARS- CoV-2 plus AIH (n = 70); 
86% immunosuppression; SARS- CoV-2 plus 
non- AIH CLD (n = 862); SARS- CoV-2 plus 
non- CLD (n = 769)
Immunosuppression not an independent risk factor for 
death in patients with AIH; equivalent rates of mortality 
for patients with AIH vs non- AIH CLD; higher rates of 
hospitalization but equivalent rates of mortality for 
patients with AIH compared to non- CLD
Summary of studies investigating the effect of SARS- CoV-2 infection on patients with chronic liver disease separated by disease aetiology or post liver transplantation. 
AIH, autoimmune hepatitis; ALD, alcohol- related liver disease; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus 
diseases 2019; CP, Child–Pugh; CVD, cardiovascular disease; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ICU, intensive care unit; 
IPPV, invasive positive pressure ventilation; LT, liver transplant; NAFLD, nonalcoholic fatty liver disease; SARS- CoV-2, severe acute respiratory syndrome coronavirus 2; 
SIR, standardized incidence ratio; SMR, standardized mortality ratio; T2DM, type 2 diabetes mellitus.
Table 1 (cont.) | Summary of COVID-19 outcome studies in patients with CLD and post- liver transplantation
less likely to receive targeted antiviral therapy than those 
without (33% versus 52%; P < 0.001)91. This finding 
might reflect prescribing concerns and demonstrates 
the need for COVID-19 trials to carefully evaluate drug 
hepatotoxicity to prevent patients with cirrhosis, who are 
already at high risk of death, from being unnecessarily 
denied disease- modifying treatment.
Clinical course and outcomes of SARS- CoV-2 infection in 
liver transplant recipients. In population terms, SARS- 
CoV-2 infections in liver transplant (LT) recipients are 
relatively uncommon. However, there is keen interest in 
the effect of SARS- CoV-2 on this patient cohort, who 
have frequent exposure to health- care facilities and 
frequent concurrent comorbidities and among whom 
the majority have an absolute requirement for chronic 
immunosuppression113,114.
Assessing the susceptibility of LT recipients to 
SARS- CoV-2 infection is challenging because of geo-
graphical and chronological variability in diagnostic 
methods, thresholds for testing and individual expo-
sures. Nonetheless, country- wide data from Spain and 
the UK suggest that diagnoses of SARS- CoV-2 are more 
frequent among LT recipients than among the gen-
eral population, although this finding might be partly 
attributable to more intensive monitoring and a lower 
threshold for viral testing in the liver transplantation 
setting115,116. Further data from primary care cohorts will 
increase our understanding of this area but will require 
careful correlation with contemporary epidemiology.
It is clear that not all LT recipients diagnosed with 
SARS- CoV-2 infection develop severe COVID-19. 
For example, in the Spanish series (n = 111), 6% were 
described as asymptomatic and, in a multinational 
series (n = 151), 14% had neither respiratory nor gastro-
intestinal symptoms115,117. In a German study that used 
serology to identify LT recipients with likely previous 
exposure to SARS- CoV-2, 5 of 8 individuals with a 
detectable IgG response reported no previous symptoms 
consistent with COVID-19 (ref.118).
In those who develop symptoms, the key respiratory 
features of COVID-19 appear similar in those with and 
without liver transplatation, with fever, cough and dysp-
noea developing around 1 week following SARS- CoV-2 
infection. In patients hospitalized with severe disease, 
marked elevations in ferritin, D- dimer and IL-6 levels 
alongside lymphopenia on laboratory assays, and dif-
fuse parenchymal opacities without pleural effusion on 
chest radiology are well- recognized119,120. One difference 
among LT recipients seems to be a high frequency of 
gastrointestinal symptoms, with diarrhoea reported in 
31% and 42% of two early cohorts, respectively119,120. In a 
Systemic inflammation Acute hepatic
decompensation and ACLF
↓ T lymphocyte frequency
and proliferation
↓ B lymphocyte frequency
↓ CD24+ memory cells









Fig. 3 | Possible mechanisms for adverse COVID-19 outcomes in patients with cirrhosis. Patients with cirrhosis  
have a high risk of mortality from respiratory failure following severe acute respiratory syndrome coronavirus 2 
(SARS- CoV-2) infection. This risk might occur through multiple converging pathways, including contributions  
from cirrhosis- associated immune dysfunction, acute hepatic decompensation and a systemic inflammatory response. 
Cirrhosis- associated immune dysfunction could also lead to defective immune responses following future SARS- CoV-2 
vaccination. ACLF, acute- on- chronic liver failure; COVID-19, coronavirus disease 2019.
propensity- matched analysis, gastrointestinal symptoms 
were also more frequent among patients with LT than in 
those without117.
Assessing the outcomes associated with liver trans-
plantation among individuals infected with SARS- 
 CoV-2 is complicated by the demography and pattern 
of comorbidity within the population. LT recipients are 
more likely to be male121 and more likely to have renal 
impairment122, type 2 diabetes mellitus123 and obesity124 
than the general population. Furthermore, the age 
of LT recipients is increasing, with a median recipient 
age in both the USA and the UK of 56 years125. All of 
these factors are well established as being associated 
with an increased risk of adverse outcomes following 
SARS- CoV-2 infection and these risks seem to apply 
to LT recipients. Within cohort studies of LT recipients, 
age and burden of comorbidity (for example, Charlson 
Comorbidity Index) are strongly associated with death 
or severe disease course115,117. Although only a minority 
of LT recipients have clinically significant liver dysfunc-
tion, if present, this aspect could logically be considered 
a possible additional risk factor for severe COVID-19 
as described elsewhere in this Review126.
When considering the risk conveyed by liver trans-
plantation itself in the context of SARS- CoV-2 infection, 
adjustment for concurrent comorbidity is required. 
Clinical data incorporating such adjustments suggest 
that LT recipients are not at increased risk of severe 
COVID-19 or death as compared to non- LT recipi-
ents115,117. Notably, such data derived from registry 
work are open to reporting biases, although case fatality 
rates are broadly consistent across cohort studies from the 
first wave of the pandemic at around 20%115–117,119,127. 
Importantly, the observation of there being no increased 
risk of severe COVID-19 seems to hold true when 
comparing the national LT and non- LT populations in 
Spain115. Furthermore, work combining a large cohort of 
primary care records and hospital episodes in the UK has 
confirmed an increased risk of death from COVID-19 
in patients with CLD but shown no statistically signif-
icant difference in mortality in non- renal solid organ 
recipients128. When considering the relative importance 
of comorbidity, it is notable that in pooled data from the 
two large cohorts of SARS- CoV-2 infection in LT recip-
ients, no patient with a Charlson Comorbidity Index of 
0 died (points are attributed for age >50 years but not 
LT itself129.
The current understanding that liver transplantation 
and the associated immunosuppression itself do not 
seem to confer an increased risk of poor outcome in 
SARS- CoV-2 infection is consistent with other observa-
tions. First, typical immunosuppression for LT recipients 
primarily limits the adaptive immune response rather 
than the innate response, with the latter seeming pri-
mary in determining COVID-19 outcome130. The only 
form of immunosuppression strongly linked with poor 
outcomes identified to date is of specific deficits in the 
type I interferon innate response131,132. Second, reactive 
corticosteroid immunosuppression with high- dose 
dexamethasone reduces mortality in severe COVID-19 
(ref.133). Third, as noted by others, immunosuppression, 
including for liver transplantation, did not emerge as a 
risk factor for poor outcome in SARS- CoV-1 or Middle 
Eastern Respiratory Syndrome infections, whereas 
comorbidities analogous to those conferring risk in 
SARS- CoV-2 infection did134. Interestingly, the fact that 
LT recipients have similar outcomes to the matched 
general population is in stark contrast to the very high 
rates of mortality reported in those with advanced liver 
disease. This finding might suggest that, in the context 
of COVID-19, immunosuppression secondary to CAID 
has a more deleterious effect than pharmacological 
immunosuppression.
It therefore remains the case that major international 
guidelines currently recommend against the routine 
cessation or reduction of immunosuppressive therapy 
in LT recipients before any SARS- CoV-2 infection and 
that modification following SARS- CoV-2 be considered 
under special circumstances such as in superadded bac-
terial infection or worsening respiratory failure103,104,135. 
As already discussed, disturbances of liver biochemistry 
are frequent in COVID-19 but seem to be an indirect 
effect of SARS- CoV-2 infection analogous to that seen 
in the cytokine storm in other situations55,57,130. Although 
liver injury — as defined by elevated serum transami-
nase activities — occurs in LT recipients and is associ-
ated with mortality, it seems either no more frequent or 
less frequent than in comparison groups117,127.
Whilst data about differences on SARS- CoV-2 infec-
tion in those with LT is accumulating, numerous issues 
remain (box 1). However, to date, it seems clear that 
the weight of comorbidity is more important in deter-
mining outcome than LT status per se and that being 
an immunosuppressed LT recipient confers less risk 
from SARS- CoV-2 than having advanced CLD, thereby 
supporting the continuation of liver transplantation 
programmes.
Challenges and considerations with SARS- CoV-2 vac-
cination in patients with CLD. SARS- CoV-2 vaccine 
development has progressed at an unprecedented rate. 
The Pfizer/BioNTech BNT162b2 mRNA, Moderna 
mRNA-1273, AstraZeneca/University of Oxford 
ChAdOx1- nCoV-19 chimpanzee adenovirus vector 
vaccine and the heterologous recombinant adenovirus- 
based Gam- COVID- Vac (Sputnik V) have each reported 
excellent safety profiles and marked efficacy in prevent-
ing symptomatic COVID-19 (62–95%)136–139. Despite the 
inclusion of over 100,000 participants in phase III trials, 
data in patients with liver disease are limited, represent-
ing less than 0.5% of those enrolled. Therefore, as vac-
cines accelerate into licensing and deployment, it is now 
vital to consider the specific implications for individual 
disease states, including CLD140.
Cirrhosis is associated with both systemic inflamma-
tion and innate and adaptive immune dysfunction predis-
posing to infection- related morbidity and mortality141–143. 
Similarly, patients with cirrhosis have been shown to 
have impaired responses to existing licensed vaccina-
tions such as those for pneumococcus and hepatitis B 
virus144,145 (fig. 3). Whilst it is biologically plausible that 
patients with cirrhosis might also respond poorly to 
SARS- CoV-2 vaccination, current data to support this 
notion are lacking. It is therefore difficult to speculate as 
to which vaccine type might be most effective for patients 
with cirrhosis or whether modifications to the standard 
vaccine dosing or timing will be required. Similarly, the 
immunogenicity of SARS- CoV-2 vaccines in LT recipi-
ents and immunosuppressed patients with autoimmune 
liver disease remains to be determined, with these groups 
also known to have attenuated responses to vaccinations 
against other diseases146.
Neither the adenoviral vector nor the mRNA vaccine 
platforms contain live or attenuated virus and it there-
fore seems unlikely that immunization represents a par-
ticular safety concern for liver disease cohorts. Whilst 
historically there have been anxieties that vaccination 
in solid organ transplant recipients might lead to the 
development of alloimmunity and graft rejection, no 
clinical evidence has ever emerged to support this con-
cern146. In light of the high COVID-19- related mortality 
in patients with decompensated cirrhosis, it remains of 
utmost importance to prioritize vaccination in this sub-
group. Although LT recipients have comparable rates 
of COVID-19- related mortality to the matched general 
population117, they do have higher rates of admission to 
intensive care and could have been relatively more pro-
tected throughout the pandemic due to enhanced social 
distancing. Thus, this group remain a vulnerable popula-
tion and should also be prioritized for vaccination, with 
the benefits far outweighing the potential risks. These 
principles regarding the prioritization of vaccine deliv-
ery are reflected in the American Association for the 
Study of Liver Diseases (AASLD) consensus statement 
on COVID-19 vaccination in patients with liver disease, 
published in January 2021 (ref.147).
As COVID-19 vaccines are disseminated glob-
ally, it will be crucial to monitor for post- vaccination 
infection in patients with CLD. This may be facilitated 
though existing international registry platforms such as 
COVID-Hep (supported by the European Association 
for the Study of the Liver) and SECURE-Liver (for-
merly known as SECURE-Cirrhosis) (supported by the 
American Association for the Study of Liver Diseases). 
This real- world data collection should occur in paral-
lel with detailed mechanistic work assessing T cell and 
humoral immune responses after vaccination in liver 
subpopulations. Ideally, this should involve a coordinated 
response from the hepatology community to account for 
heterogeneity between vaccine candidates, laboratory 
immune assays and liver disease phenotype.
COVID-19 pandemic on hepatology care
During the early phase of the COVID-19 pandemic, the 
prevention, control and management of SARS- CoV-2- 
 infected patients rightfully took centre stage and it was 
therefore reasonable to reduce and postpone services 
for other non- urgent medical conditions. Nonetheless, 
such policies will inevitably have collateral downstream 
effects on patients, including those with CLD. With time, 
because of the delayed diagnosis and treatment of vari-
ous liver diseases, there will be escalating morbidity and 
mortality148 (fig. 4).
Cirrhosis. In patients with cirrhosis, it is important to 
treat the underlying liver disease, screen for hepato-
cellular carcinoma (HCC) and varices, and promptly 
detect and treat complications of cirrhosis 106,149. All 
these strategies might be affected during the pandemic. 
For instance, the delayed initiation of antiviral therapy 
in patients with chronic viral hepatitis and the relapse of 
problem drinking could lead to disease progression and 
decompensating events150. Postponing routine therapeu-
tic paracentesis for tense ascites might convert an elective 
procedure into one requiring emergency hospitaliza-
tion. Acute variceal haemorrhage could also develop in 
patients without timely endoscopic surveillance.
Hepatocellular carcinoma. Currently, both the AASLD 
and the European Association for the Study of the Liver 
(EASL) support the resumption of HCC surveillance 
in high- risk patients (for example, advanced cirrhosis, 
chronic hepatitis B virus infection) during the COVID-19 
Box 1 | Key unresolved issues for SARS- CoV-2 infection in LT recipients
Susceptibility and disease course
•	What is the role of health- care exposure? Health- care acquisition in liver transplant
(lT) recipients has been reported118; it is unclear as to the optimum method of
minimizing this exposure.
•	Is recurrent infection more likely? With early reports of reinfection in non- transplant
patients, it remains unknown as to whether lT recipients with impaired adaptive 
responses will be susceptible to reinfection183.
•	Is viral shedding prolonged in lT recipients? Case reports suggest prolonged viral
shedding in some lT recipients, which might have public health implications184.
•	Is the post- infection immune response durable? early reports suggest that the 
neutralizing IgG response to severe acute respiratory syndrome coronavirus 2 
(SaRS- Cov-2) is of variable duration185. This aspect is unexplored in lT recipients.
It is unclear whether a protective post- infection immune response will persist after
transplantation.
•	Is the apparent increased frequency of gastrointestinal symptoms of clinical 
importance? Gastrointestinal symptoms seem more frequent in lT recipients;
the importance of this finding remains unclear.
Therapeutics and clinical management
•	Caution with drug–drug interactions with novel therapies: drug interactions are 
frequent in transplant recipients, especially with calcineurin inhibitors, and must
be considered with future novel therapies.
•	Caution with putative future therapies that act to stimulate aspects of the immune 
response: putative coronavirus disease 2019 (CovID-19) therapies, such as interferon
or checkpoint inhibition, might have severe adverse effects in lT recipients186,187.
•	The value of additional immunosuppression in severe CovID-19: it is unclear as to 
whether the benefit of dexamethasone that was demonstrated in those with severe
CovID-19 applies to those already immunosuppressed133. equally, the cytokine
response to SaRS- Cov-2 in lT recipients is undefined.
Immunization
•	Response to SaRS- Cov-2 vaccination: lT recipients typically have reduced rates
of seroconversion and reduced antibody titres in response to vaccination188.
•	Duration of any response to SaRS- Cov-2 vaccines: duration of immune response
to vaccination might be reduced in lT recipients.
Immunosuppression
•	optimal long- term immunosuppressant regimen: whether interindividual variations 
in immunosuppression affect disease susceptibility is undefined; some have suggested 
a negative effect of mycophenolate but this issue has not been confirmed115,180.
•	The characteristics of infection in the immediate post- operative course are undefined: 
patients in the immediate post- operative period are typically more substantially 
immunosuppressed (including potentially with depleting antibodies) and might have 
a different response to SaRS- Cov-2.
pandemic but recognize potential feasibility issues due to 
the strain on imaging and radiology resources103,104. The 
AASLD, therefore, recognises that an arbitrary delay of 
2 months might be reasonable following the discussion 
of risks and benefits with the patient104. If HCC surveil-
lance is deferred indefinitely, it is inevitable that the pro-
portion of patients presenting with HCC not amenable to 
curative treatments will increase151. The proper manage-
ment of HCC requires input from hepatologists, surgeons, 
intervention radiologists, oncologists and allied health 
workers, and therefore the maintenance of multidisci-
plinary care via telemedicine should be actively pursued. 
However, a multicentre study within the metropolitan 
area of Paris, France, during a period of high SARS- 
CoV-2 infection prevalence demonstrated a statistically 
significant reduction in the number of HCC diagnoses 
and double the rate of HCC treatment delay compared 
with the same period the previous year152. Nevertheless, 
the HCC treatment modality, including liver surgery, 
remained unchanged between the two time periods.
Liver transplantation. Liver transplantation programmes 
have been affected by the pandemic in a multitude of 
ways153,154. First, the recommendation against using 
organs from deceased donors with SARS- CoV-2 infec-
tion is consistent across all major guidelines155. Similarly, 
to avoid the risk of SARS- CoV-2 exposure and transmis-
sion, live donor transplantation has often been reduced 
or suspended103,104. During times of peak SARS- CoV-2 
infection the strain on hospital resources, and particularly 
ICU availability, has meant that, for certain periods, liver 
transplantation has been reserved only for super- urgent 
and highly urgent cases156. Accordingly, data from both 
the American United Network for Organ Sharing–Organ 
Procurement Transplant Network and the UK National 
Health Service Blood and Transplant service show a 
clear inverse correlation between transplant activity 
and national rates of SARS- CoV-2 infection, with liv-
ing donor liver transplantations most affected (fig. 5). 
In order to maintain some transplant service provision, 
the pathways for organ procurement have had to remain 
flexible, with donors being sent to recipient centres or 
local organ retrieval and/or surgical teams from recipient 
centres travelling to donor hospitals.
Elimination of viral hepatitis. In 2017, the WHO pub-
lished the first Global Hepatitis Report and set the aim 
to eliminate viral hepatitis as a major public health threat 
by 2030 (ref.157). Since then, healthcare providers, policy- 
makers and patients have joined forces to scale- up 
screening, diagnosis, assessment and treatment of viral 
hepatitis. During the COVID-19 pandemic, although 
different countries have adopted measures, such as tele-
medicine and automatic drug refill, to ensure the con-
tinuation of current antiviral therapies, there has been 
a major impact on new case identification and treat-
ment initiation. In a modelling study for 110 countries/
territories, a 1- year delay in the progress of the hepati-
tis elimination programme is estimated to increase the 
number of HCC and liver- related deaths by 44,800 and 
72,300, respectively158. However, despite these under-
standable concerns, there could be some positive ways 
to harness the widespread practical changes forced by 
the pandemic. For example, the decentralization of elim-
ination efforts through postal blood- spot testing and 
medication delivery might have sustainable long- term 
benefits. Furthermore, political and health- care systems 
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Fig. 4 | Trends in liver disease risk factors and management and possible future effect on liver disease incidence 
and severity. Trends over time in liver disease risk factors and hepatology care provision in relation to the onset of the 
coronavirus disease 2019 (COVID-19) pandemic and the cumulative short- term, medium- term and long- term effects this 
pandemic might have on liver health. HCC, hepatocellular carcinoma; IP, inpatient; SARS- CoV-2, severe acute respiratory 
syndrome coronavirus 2; UGI, upper gastrointestinal; USS, ultrasound scan.
contact tracing and vaccination delivery. There might 
now be an opportunity to harness this infrastructure 
to help combat chronic viral hepatitis at a population 
level159. This progress will also go hand- in- hand with 
other adaptations to health- care delivery such as tele-
medicine, remote monitoring and greater interaction 
with caregivers at home. These all represent promising 
opportunities to help deliver good hepatology care not 
only for viral hepatitis but across the spectrum of liver 
disease type and severity160.
Liver research. COVID-19 has had a major effect on 
liver research, especially clinical trials, due to uncer-
tainties surrounding infection control and difficulties 
adhering to the study protocols161. The follow- up, 
assessment and distribution of investigational products 
could all be hampered by quarantine measures and par-
ticipant illness. For these reasons, many sponsors have 
stopped new case recruitment into clinical trials, which 
is likely to delay important drug development. It is 
therefore currently important to consider flexible solu-
tions such as replacing less critical visits with phone 
or video calls, remote monitoring using local labora-
tories, and direct shipment of investigational products 
to the patients. There are also concerns about research 
funding due to economic downturn in the next few 
years162. The negative impact of the pandemic on exist-
ing non- COVID-19 basic and translational research 
must also not be underestimated. Institutions across the 
globe have endured major research set- backs, includ-
ing laboratory closures, diversion of resources towards 
COVID-19 studies, and the loss of cell lines and animal 
models during national lockdowns163. Furthermore, 
the cancellation or postponement of national and 
international conferences has disrupted the valuable 
exchange of scientific information. In recovering from 
the COVID-19 pandemic it is therefore vital that policy 
and funding is structured in a way that helps rejuvenate 
basic science research activity.
COVID-19 pandemic and patient behaviours
The COVID-19 pandemic has understandably mod-
ified human behaviour beyond recognition. However, 
some of these behaviours could negatively influence liver 
health, particularly with respect to alcohol use, diet and 
exercise, and patient interactions with medical services.
An increased alcohol consumption is now a well- 
 recognized feature of the pandemic, particularly dur-
ing periods of social isolation. In the weeks leading up 
the first national ‘lockdown’ in the UK, an additional 
£160  million were spent stockpiling alcohol com-
pared with the same timeframe the previous year164,165. 
Furthermore, nationwide consumer data from the UK 
have shown a pervasive elevation in alcohol purchasing 
amongst all but the very poorest in society166,167. Data on 
alcohol sales have shown similar trends in the USA168. 
This change in behaviour has translated into harmful 
drinking habits, with national and international surveys 
consistently demonstrating an increase in regular alco-
hol use during the first wave of COVID-19 (refs169–171) 
and an overall escalation in alcohol consumption repor-
ted in up to 48% of respondents170. In addition, 17% of 
abstinent individuals with a history of alcohol use disor-
der were found to relapse to drinking under lockdown 
conditions172. This finding contrasts with a decline in 
smoking, mostly due to a reduction in the number of 
lighter smokers169. Single- centre observations in the UK 
have also shown that referrals for alcoholic liver disease 
(ALD) and the proportion of critically unwell inpa-
tients with ALD (but without COVID-19) more than 
doubled in June 2020 compared with June 2019 (ref.173). 
The upsurge in harmful drinking, alongside barriers 
to cessation services and the association between ALD 
and COVID-19 mortality (discussed earlier) is of major 
concern and suggests that alcohol advice should be 
central to the health messages delivered to patients and 
the general public during the pandemic.
The pandemic has also propagated unhealthy life-
styles predisposing to NAFLD. A study in northern 
Italy found that patients with obesity gained an aver-
age of 1.5 kg in weight during the national quarantine, 
in parallel with reduced exercise, excess calory intake, 
and increased self- reported anxiety and depression174. 
Similarly, a US survey of over 4,000 patients with dia-
betes found that one- third reported a less healthy diet 
and half reported performing less exercise during the 
pandemic175. Despite these observations, no study has 
yet directly evaluated the incidence of NAFLD in the 
COVID-19 era.
Lastly, the interaction of patients with secondary 
care services has changed. National US data from the 
Veterans Health Administration showed that that hospi-
talizations with cirrhosis decreased by a third following 
the onset of the pandemic compared with the previous 
year, with a significant increase in the severity of liver 
disease in those who were admitted176. This might reflect 
patient concerns about potential SARS- CoV-2 exposure 




















































Fig. 5 | UK Liver transplant activity before and during COVID-19 pandemic. United 
Kingdom National Health Service Blood and Transplant service data on liver transplant 
activity before and during the coronavirus disease 2019 (COVID-19) pandemic. The data 
for fig. 5 that support the plots within this paper are available from the NHS Blood and 
Transplant Organ Donation and Transplantation Reports and the Coronavirus (COVID-19) 
in the UK website. SARS- CoV-2, severe acute respiratory syndrome coronavirus 2.
Conclusions
The hepatic consequences of SARS- CoV-2 infection 
are now recognized as an important component of 
COVID-19. This aspect is most clinically relevant in 
patients with pre- existing cirrhosis who are at remark-
ably high risk of severe COVID-19 and death. Whilst 
further work is required to understand the pathogenic 
mechanisms that drive this clinical deterioration, there 
are likely to be contributions from systemic inflamma-
tion, disordered coagulation and immune dysfunction. 
Although a range of in vitro and in vivo models have 
been used to help decipher the specific hepatotropism 
of SARS- CoV-2, the clinical impact of direct viral 
infection of liver cell types remains to be determined. 
The grave prognosis with COVID-19 in patients with 
cirrhosis contrasts with the LT population who have 
comparably better outcomes. It therefore seems that 
cirrhosis- associated immune dysfunction has a far 
more detrimental effect on the COVID-19 course than 
pharmacological immunosuppression. With efficacious 
SARS- CoV-2 vaccines now available, patients with cir-
rhosis should be seen as a priority for immunization 
and the hepatology community should prepare to care-
fully monitor the immune response in this subpopu-
lation. Lastly, we must all be aware of the profound 
negative effect of the pandemic on liver services and 
unhealthy patient behaviours, which might culminate 
in an increase in the global burden of liver disease in the 
coming months and years.
Data availability
The UK Liver transplant and coronavirus data that 
support the plots within this paper are available from 
the NHS Blood and Transplant Organ Donation and 
Transplantation Reports website at https://www.odt.
nhs.uk/statistics- and- reports/ and the Coronavirus 
(COVID-19) in the UK website at https://coronavirus.
data.gov.uk/.
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